ixekizumab
autoallergy
vobarilizumab
tabalumab
autoimmunology
autocentromere
ocrelizumab
tocilizumab
autoproliferation
sarilumab
cedelizumab
talizumab
autoimmunization
fontolizumab
antimonoclonal
atezolizumab
sonepcizumab
tucotuzumab
autoimmunological
autoinflammation
elotuzumab
muromonab
bivatuzumab
gevokizumab
brolucizumab
ravulizumab
autoepitope
amlitelimab
teplizumab
pidilizumab
abagovomab
tislelizumab
autoimmunity
olaratumab
dorlixizumab
intetumumab
glembatumumab
zanolimumab
dacetuzumab
soravtansine
otilimab
-lim-
-les-
autovaccine
autoimmunologically
autoimmune
intrabody
systemic lupus erythematosus
bezlotoxumab
immunopanning
ipilimumab
pathoantigen
epratuzumab
brazikumab
pancytokeratin
ziltivekimab
sintilimab
pozelimab
samalizumab
lintuzumab
vanucizumab
matuzumab
sasanlimab
inotuzumab ozogamicin
toripalimab
tisotumab
afasevikumab
zenocutuzumab
dinutuximab
retifanlimab
guselkumab
evolocumab
olendalizumab
sibrotuzumab
solitomab
onartuzumab
antiantibody
carlumab
heterophile
efalizumab
perakizumab
alloantibody
otelixizumab
antigenomic
clenoliximab
immunosorbing
-kin-
agonistic monoclonal antibody
autoaggression
immunosphere
immunoprecipitant
polyvalent
monospecific
immunothrombocytopenia
dalotuzumab
autoimmunologic
ozoralizumab
cergutuzumab
iccosome
-zumab